Zobrazeno 1 - 10
of 38
pro vyhledávání: '"Ashit, Trivedi"'
The process of drug discovery and development is a complex multistage logistics project spanned over 10-15 years with an average budget exceeding 1 billion USD. Starting with target identification and synthesizing anywhere between 10k to 15k syntheti
Autor:
Ashit Trivedi, Winnie Sohn, Priyanka Kulkarni, Pegah Jafarinasabian, Hanze Zhang, Marintan Spring, Stephen Flach, Siddique Abbasi, Jan Wahlstrom, Edward Lee, Sandeep Dutta
Publikováno v:
Clinical and Translational Science, Vol 14, Iss 6, Pp 2510-2520 (2021)
Abstract Omecamtiv mecarbil (OM) is a novel cardiac myosin activator in development for the treatment of heart failure. In vitro, OM is an inhibitor of BCRP. Rosuvastatin, a BCRP substrate, is one of the most commonly prescribed medications in patien
Externí odkaz:
https://doaj.org/article/86aa2e97af2349d6999630760b8de569
Autor:
Ashit Trivedi, Y.-H. Kiang, Robert E. Saw, Guilong Charles Cheng, Omar Mather, Silvia Vega, Jennifer Hellawell, Edward Lee
Publikováno v:
Drugs in R&D. 22:147-154
AMG 986 is a first-in-class, novel apelin receptor small molecule agonist initially developed for the treatment of heart failure. The current phase I study was conducted to evaluate the pharmacokinetics and safety of a single-dose 200-mg capsule form
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::827248f640ce448856b24b1346f53a1c
https://doi.org/10.1007/s40268-022-00388-1
https://doi.org/10.1007/s40268-022-00388-1
Autor:
Karen Santos, Pradeep B. Lukka, Anne Grzegorzewicz, Mary Jackson, Ashit Trivedi, Fernando Pavan, Marlus Chorilli, Miriam Braunstein, Anthony Hickey, Bernd Meibohm, Mercedes Gonzalez-Juarrero
Publikováno v:
Frontiers in Microbiology, Vol 9 (2018)
There is an urgent need to treat tuberculosis (TB) quickly, effectively and without side effects. Mycobacterium tuberculosis (Mtb), the causative organism of TB, can survive for long periods of time within macrophages and dendritic cells and these in
Externí odkaz:
https://doaj.org/article/474f7a8a8f054cdf9c76928c6f2b5eec
Publikováno v:
Drugs in R&D. 22:89-94
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9613e59d9d6d918af07cee0a278fbe31
https://doi.org/10.1007/s40268-021-00380-1
https://doi.org/10.1007/s40268-021-00380-1
Autor:
Winnie Sohn, Jan Wahlstrom, Marintan Spring, Hanze Zhang, Siddique Abbasi, Stephen Flach, Sandeep Dutta, Priyanka Kulkarni, Ashit Trivedi, Edward Lee, Pegah Jafarinasabian
Publikováno v:
Clinical and Translational Science
Clinical and Translational Science, Vol 14, Iss 6, Pp 2510-2520 (2021)
Clinical and Translational Science, Vol 14, Iss 6, Pp 2510-2520 (2021)
Omecamtiv mecarbil (OM) is a novel cardiac myosin activator in development for the treatment of heart failure. In vitro, OM is an inhibitor of BCRP. Rosuvastatin, a BCRP substrate, is one of the most commonly prescribed medications in patients with h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ccbdbcaab55c6640e6a082227a797fa
https://doi.org/10.1111/cts.13118
https://doi.org/10.1111/cts.13118
Autor:
Sandeep Dutta, Bianca Terminello, Pegah Jafarinasabian, Winnie Sohn, Siddique Abbasi, Hanze Zhang, Edward Lee, Ashit Trivedi, Stephen Flach
Publikováno v:
Clinical Pharmacology in Drug Development. 11:129-133
Omecamtiv mecarbil (OM) is a novel cardiac myosin activator in development for the treatment of heart failure (HF) with reduced ejection fraction. OM is administered as a 25-, 37.5-, or 50-mg modified-release formulation in patients with HF. Proton p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e7002da55d84c07feb588158b398fe7
https://doi.org/10.1002/cpdd.997
https://doi.org/10.1002/cpdd.997
Autor:
Stephen Flach, Ashit Trivedi, Siddique Abbasi, Sandeep Dutta, Fady I. Malik, Hanze Zhang, Pegah Jafarinasabian, Edward Lee
Publikováno v:
Clinical Pharmacology in Drug Development. 11:185-193
Omecamtiv mecarbil (OM) is a cardiac myosin activator under development for the treatment of heart failure. The effect of CYP3A4 and CYP2D6 inhibition on OM pharmacokinetics and the potential for OM to induce CYP3A4 was assessed in 2 studies. Study 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b2325e61a132921e8e2e304314d035c
https://doi.org/10.1002/cpdd.987
https://doi.org/10.1002/cpdd.987
Autor:
Edward Lee, Mia Mackowski, Hanze Zhang, Sandeep Dutta, Ashit Trivedi, Stephen Flach, Ajay Bhatia, Pegah Jafarinasabian, Bianca Terminello
Publikováno v:
Clinical Drug Investigation. 41:639-645
Omecamtiv mecarbil (OM) is a cardiac myosin activator under clinical development for the treatment of heart failure. Two modified-release (MR) novel OM minitablet formulations were developed to support the planned investigation of chronic heart failu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c84210269594e679598ff41e3854884
https://doi.org/10.1007/s40261-021-01052-3
https://doi.org/10.1007/s40261-021-01052-3
Autor:
Hanze Zhang, Pegah Jafarinasabian, Shauna Hutton, Siddique Abbasi, Mia Mackowski, Rajneet K. Oberoi, Stephen Flach, Edward Lee, Sandeep Dutta, Ashit Trivedi
Publikováno v:
Clinical Pharmacology in Drug Development. 10:1442-1451
Omecamtiv mecarbil (OM) is a novel selective cardiac myosin activator under investigation for the treatment of heart failure with reduced ejection fraction. OM is primarily eliminated via metabolism mediated by multiple cytochrome P450 enzymes. This
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b2cc4c0ae2722baff2608d90168dfbeb
https://doi.org/10.1002/cpdd.969
https://doi.org/10.1002/cpdd.969